SINDROMUL HEPATO-PULMONAR (SHP)

  • Laura BOZOMITU Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • Evelina MORARU Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • B. STANA Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • M. BURLEA Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • G. APRODU Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • D. MORARU Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
Keywords: HEPATO- -PULMONARY SYNDROME, LIVER CIRRHOSIS, PORTAL HYPERTENSION

Abstract

The hepato-pulmonary syndrome (HPS)
is a rare complication of liver cirrhosis, with poor outcome; the term includes liver disease,
increased alveolo-arterial gradient and intrapulmonary vascular dilations, described by Fluckiger,
Kennedy and Knudson. HPS impairs survival in cirrhotic patients and the posttransplant
outcome is altered in correlation with severity of HPS. Combined determination of SaO2 in
clino- and orthostatic position by a pulsoximeter is a simple test for HPS identification in
patients with chronic liver disease or non-cirrhotic portal hypertension.

Author Biographies

Laura BOZOMITU, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Clinica a V-a Pediatrie

Evelina MORARU, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã

Clinica a II-a Pediatrie

B. STANA, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã

Clinica a II-a Pediatrie

M. BURLEA, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Clinica a V-a Pediatrie

G. APRODU, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã

Clinica de Chirurgie Pediatricã

D. MORARU, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Clinica a V-a Pediatrie

References

1. Palma DT, Fallon M. The hepatopulmonary syndrome. J Hepatol 2006; 45: 617-625.
2. Lenaerts C. Cystic fibrosis-associated liver disease. JPGN 2004; 5: 566- .
3. Cremona G, Higenbottam TW, Mayoral V et al. Elevated exhaled nitric oxide in patients with
hepatopulmonary syndrome. Eur Respir J 1995; 8: 1883–1885.
4. Schenk P, Madl C, Rezale-Majd S, Lehr S, Muller C. Methylene blue improves the hepatopulmonary
syndrome. Ann Int Med 2000; 133: 701–706.
5. Arguedas MR, Drake BB, Kapoor A, Fallon MB. Carboxyhemoglobin levels in cirrhotic patients
with and without hepatopulmonary syndrome. Gastroenterol 2005; 128: 328–333.
6. Chang SW, Ohara N. Pulmonary circulatory dysfunction in rats with biliary cirrhosis. An animal
model of the hepatopulmonary syndrome. Am Rev Respir Dis 1992; 145: 798–805.
7. Luo B, Tang L, Zhang J et al. Biliary epithelial derived endothelin-1: an endocrine mediator of
experimental hepatopulmonary syndrome. Hepatol 2004; 40: 214.
8. Luo B, Tang L, Wang Z et al. Cholangiocyte endothelin-1 and transforming growth factor-beta1
production in rat experimental hepatopulmonary syndrome. Gastroenterol 2005; 129: 682–695.
9. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observations and
lack of therapeutic response to somatostatin analogue. Chest 1993; 104: 515–521.
10. Arguedas M, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and
predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation.
Hepatol 2003; 37: 192–197.
Published
2019-04-14
Section
INTERNAL MEDICINE - PEDIATRICS